Effects of a specific thromboxane synthetase inhibitor on thromboxane generation and excretion in healthy dogs.

Abstract

A specific thromboxane synthetase inhibitor, 3-methyl-2 (3-pyridyl)-1-indoleoctanoic acid (CGS 12970) was administered orally to 6 healthy adult Beagles at a dosage of 30 mg/kg of body weight. Blood generation of thromboxane B2 and urinary excretion of thromboxane B2 were measured before and after administration of CGS 12970. Although 97 +/- 0.4% inhibition of thromboxane B2 generation was observed within 2 hours after a single dose of CGS 12970 was administered orally, an effect on urinary excretion of thromboxane B2 was not observed. Additionally, oral administration of 30 mg/kg every 12 hours resulted in 80 +/- 14% inhibition of thromboxane B2 generation but had no effect on urinary thromboxane B2 excretion.

• Authors: S L Longhofer, H C Johnson, C A Culham, K T Schultz, G F Grauer
• Journal: American journal of veterinary research (Am J Vet Res) Vol. 51 Issue 11 Pg. 1746-50 (Nov 1990) ISSN: 0002-9645 [Print] United States
• PMID: 2240799 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Pyridines
• Thromboxane B2
• 3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid
• Thromboxane-A Synthase

Topics

• Administration, Oral
• Animals
• Dogs (blood, metabolism)
• Kidney (enzymology)
• Male
• Pyridines (administration & dosage, blood, pharmacology, urine)
• Thromboxane B2 (biosynthesis, blood, urine)
• Thromboxane-A Synthase (metabolism, pharmacology)
• Time Factors